Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026
AI Summary
Novo Nordisk, the Danish maker of Wegovy and Ozempic, forecasts a significant revenue drop of 5% to 13% for 2026. This projection follows a challenging year where sales grew by 10% and profit before tax rose by 3%. The anticipated decline is attributed to pricing pressures from a Trump administration agreement to lower US drug prices, increasing competition from rivals like Eli Lilly, and the expiration of key patent protections for semaglutide in countries like India. While Novo Nordisk will maintain patent protection in Europe, Japan, and the US for several years, the company is launching the Wegovy pill in the US and remains confident in future volume growth despite recent market share losses and leadership changes.
Key Entities & Roles
Keywords
Sentiment Analysis
Source Transparency
This article was automatically classified using rule-based analysis. The political bias score ranges from -1 (far left) to +1 (far right).
Topic Connections
Explore how the topics in this article connect to other news stories